Boehringer Ingelheim deepens its collaboration with Click Therapeutics in a deal worth $460M

On Monday, the German pharma announced the launch of an “expanded collaboration” between Boehringer Ingelheim and Click to develop and commercialize a second “prescription-based digital therapeutic.” The collaboration will center on schizophrenia and aim to combine multiple therapeutic interventions for use with pharmaceutical therapy to help people with the disease.